All rights reserved. The Open University is authorised and regulated by the Financial Conduct Authority in relation to its secondary activity of credit broking.
Skip to main content. Search for free courses, interactives, videos and more! Free learning from The Open University. Featured content. Free courses. All content. Course content. About this free course 12 hours study. Level 3: Advanced. Course rewards. Free statement of participation on completion of these courses. Create your free OpenLearn profile. Course content Course content. Proteins Start this free course now.
Free course Proteins. Figure 33 Protein phosphorylation. Which protein domains have you come across that recognise phosphorylated amino acid residues? Figure 34 Regulation of pyruvate decarboxylase by phosphorylation. The phosphorylated enzyme is inactive. Of what kind of regulation is this an example? Feedback inhibition.
Previous 5. Next 5. Acta Neuropathol. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Interferon-gamma induces tyrosine phosphorylation of interferon-gamma receptor and regulated association of protein tyrosine kinases, Jak1 and Jak2, with its receptor.
Decker T, Kovarik P. Serine phosphorylation of STATs. Phosphoproteomics-based network medicine. An overlapping kinase and phosphatase docking site regulates activity of the retinoblastoma protein. Nat Struct Mol Biol. Competition effects shape the response sensitivity and kinetics of phosphorylation cycles in cell signaling. Ann NY Acad Sci. Lienhard GE. Non-functional phosphorylations? Weak functional constraints on phosphoproteomes. Trends Genet. Protein abundance is key to distinguish promiscuous from functional phosphorylation based on evolutionary information.
Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Systematic discovery of in vivo phosphorylation networks. Construction of human activity-based phosphorylation networks.
Mol Syst Biol. Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression. Harsha HC, Pandey A. Phosphoproteomics in cancer. Mol Oncol. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. ErbB receptors and signaling pathways in cancer. Rare and novel epidermal growth factor receptor mutations in non-small-cell lung cancer and lack of clinical response to gefitinib in two cases.
J Thorac Oncol. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med. Clinical proteomics: translating benchside promise into bedside reality. The fundamental role of epigenetic events in cancer. Nat Rev Genet. The hallmarks of cancer. The chemical biology of protein phosphorylation. Annu Rev Biochem. Tyrosine kinase - role and significance in cancer.
Int J Med Sci. Retinoblastoma: clues to human oncogenesis. Purification of DNA complementary to nucleotide sequences required for neoplastic transformation of fibroblasts by avian sarcoma viruses.
J Mol Biol. Hunter T, Cooper JA. Protein-tyrosine kinases. Sefton BM, Hunter T. From c-src to v-src, or the case of the missing C terminus. Cancer Surv. Evidence that the Abelson virus protein functions in vivo as a protein kinase that phosphorylates tyrosine. Evidence that the phosphorylation of tyrosine is essential for cellular transformation by Rous sarcoma virus. Crystal structures of c-Src reveal features of its autoinhibitory mechanism. Smart drugs: tyrosine kinase inhibitors in cancer therapy.
Cancer Cell. Biology of gastrointestinal stromal tumors. J Clin Oncol. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. Mutations in tyrosine kinase and tyrosine phosphatase and their relevance to the target therapy in hematologic malignancies.
Future Oncol. Cancer Chemother Pharmacol. Breast and prostate cancer patients differ significantly in their serum thymidine kinase 1 TK1 specific activities compared with those hematological malignancies and blood donors: implications of using serum TK1 as a biomarker. BMC Cancer. Sci Rep. A novel nuclear Src and p signaling axis controls migratory and invasive behavior in pancreatic cancer. Somatic mutations of EGFR in colorectal cancers and glioblastomas.
N Engl J Med. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Colorectal cancer: mutations in a signalling pathway. A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat Genet. Biomarkers in cancer staging, prognosis and treatment selection. Rubio-Viqueira B, Hidalgo M. Targeting mTOR for cancer treatment. Adv Exp Med Biol. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.
Dancey JE. Therapeutic targets: MTOR and related pathways. Cancer Biol Ther. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.
Ahmadian MR. Prospects for anti-ras drugs. Br J Haematol. Goodsell DS. The molecular perspective: the ras oncogene. Sawyers CL. Shifting paradigms: the seeds of oncogene addiction. Hainaut P, Plymoth A. Targeting the hallmarks of cancer: towards a rational approach to next-generation cancer therapy. Curr Opin Oncol. Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance.
Clin Pharmacol Ther. Druker BJ. Imatinib mesylate in the treatment of chronic myeloid leukaemia. Expert Opin Pharmacother. Targeted cancer therapies in the twenty-first century: lessons from imatinib. The IK3CA gene is mutated with high frequency in human breast cancers. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Epidermal growth factor receptor gene mutation status and its association with clinical characteristics and tumor markers in non-small-cell lung cancer patients in Northwest China. Mol Clin Oncol. Clin Lung Cancer. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. J Natl Cancer Inst. Hasskarl J. Sorafenib: targeting multiple tyrosine kinases in cancer.
Recent Results Cancer Res. Am J Physiol Endocrinol Metab. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Tyrosine kinase inhibitors target cancer stem cells in renal cell cancer. Oncol Rep.
The effect of seasonal variation and secretion of sunitinib in sweat on the development of hand-foot syndrome. Eur J Clin Pharmacol. Am J Physiol Renal Physiol. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.
Cutillas PR. Role of phosphoproteomics in the development of personalized cancer therapies. Proteomics Clin Appl. What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway. Cancer Discov. Personalized network-based treatments in oncology. Sci Transl Med. Murray BW, Miller N. Durability of kinase-directed therapies - a network perspective on response and resistance. Mol Cancer Ther. Strategies to overcome resistance to targeted protein kinase inhibitors.
Targeting epidermal growth factor receptor: central signaling kinase in lung cancer. Biochem Pharmacol. Keywords Keywords for this Article. Save Cancel. Share Cancel. Revoke Cancel. Flag Inappropriate The Content is. Flag Content Cancel.
Delete Content. Delete Cancel. Phosphorylation can either activate a protein orange or inactivate it green. Kinase is an enzyme that phosphorylates proteins.
0コメント